Aspen secures distribution rights in South Africa from Amgen

ASPEN PHARMACARE HOLDINGS LIMITED
(Incorporated in the Republic of South Africa) (“Aspen Holdings”)
Registration number: 1985/002935/06
Share code: APN
ISIN: ZAE000066692
LEI: 635400ZYSN1IRD5QWQ94
and its subsidiaries (collectively “Aspen” or “the Group”)

ASPEN SECURES DISTRIBUTION RIGHTS IN SOUTH AFRICA FROM AMGEN

Aspen is pleased to announce that it has concluded an agreement with Amgen, in terms of which Aspen will
exclusively market, distribute, use, and sell Amgen’s products in South Africa (the Territory) for an initial
term of 5 years, which will be renewed. Amgen is a biotechnology pioneer whose medicines reach millions
of seriously ill patients around the world. Amgen’s products include Aranesp®, Amgevita®, Prolia®,
Repatha®, NPlate®, Vectibix® and Blincyto®.

Amgen will continue to manufacture and supply its products to Aspen for the duration of the contract.

The Transaction includes future pipeline products and an opportunity for expansion of the Territory into
the rest of Sub-Saharan Africa.

The Transaction will complete by 01 July 2023.

The Transaction forms part of Aspen’s strategy to be a partner of choice to leading global pharmaceutical
and biotechnology companies for niche products in emerging markets. Amgen focuses on areas of high
unmet medical need and has a robust pipeline including biosimilars that will be registered and/or
submitted for registration in the near future. At present, Aspen is not represented in these therapeutic
areas with high growth potential.



Durban
04 May 2023

Sponsor
Investec Bank Limited




                              Confidential Corp Affairs and Business Development

Date: 04-05-2023 09:00:00

Supplied by www.sharenet.co.za
Produced by the JSE SENS Department. The SENS service is an information dissemination service administered by the JSE Limited ('JSE'). 
The JSE does not, whether expressly, tacitly or implicitly, represent, warrant or in any way guarantee the truth, accuracy or completeness of
 the information published on SENS. The JSE, their officers, employees and agents accept no liability for (or in respect of) any direct, 
indirect, incidental or consequential loss or damage of any kind or nature, howsoever arising, from the use of SENS or the use of, or reliance on,
 information disseminated through SENS.